Laekna, Inc.
來凱醫藥有限公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2105)

POSITIVE PROFIT ALERT

This announcement is made by Laekna, Inc. (the "**Company**", together with its subsidiaries, the "**Group**") pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong) (the "**SFO**").

The board (the "**Board**") of directors (the "**Directors**") of the Company is pleased to inform the shareholders of the Company (the "**Shareholders**") and potential investors that, based on the preliminary assessment of the Group's unaudited consolidated management accounts for the six months ended 30 June 2026 (the "**Reporting Period**"), the Group is expected to record:

(i) revenue in the range of approximately RMB145 million to RMB155 million for the Reporting Period, as compared to nil for the six months ended 30 June 2025 (the "**Corresponding Period**"); and

(ii) a consolidated net loss of no more than RMB5 million for the Reporting Period as compared to a consolidated net loss of approximately RMB130 million for the Corresponding Period, representing a significant decrease in loss of approximately 96% year-on-year.

The anticipated increase in revenue and significant decrease in consolidated net loss during the Reporting Period were mainly attributable to the revenue recognized under the exclusive license agreements which the Group entered into with Vasque Bio, Inc. with respect to LAE118, and Qilu Pharmaceutical Company Limited with respect to LAE002 (afuresertib).

As of the date of this announcement, the Company is still in the process of finalizing the interim results of the Group for the Reporting Period. The information contained in this announcement is only a preliminary assessment by the Board based on the unaudited consolidated management accounts of the Group for the Reporting Period currently available, which have not been reviewed by the audit committee of the Company, or reviewed by the auditors of the Company. The actual results of the Company for the six months ended 30 June 2026 may differ from the information contained in this announcement and may be subject to adjustments.

The actual results of the Group for the Reporting Period are expected to be published on 25 August 2026. The above figures are provided for Shareholders' and investors' reference only.

Shareholders and potential investors are advised to exercise caution when dealing in the securities of the Company.

By Order of the Board
Laekna, Inc.
Dr. LU Chris Xiangyang
Chairman

Hong Kong, 17 August 2026

As at the date of this announcement, the Board comprises Dr. LU Chris Xiangyang, Ms. XIE Ling and Dr. GU Xiang-Ju Justin as executive Directors; Dr. WANG David Guowei and Mr. SUN Yuan as non-executive Directors; and Dr. YIN Xudong, Dr. LI Min and Mr. ZHOU Jian as independent non-executive Directors.